Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells

The standard treatment for Triple Negative Breast Cancer (TNBC) patients is cytotoxic chemotherapy, but it is restricted since the duration of response is usually short. Blocking the PD-1/PD-L1 pathway through monoclonal antibodies (mAbs) appears to be a promising therapeutic strategy for TNBC patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Juliá, Estefanía Paula, Amante, Analía, Pampena, María Betina, Mordoh, José, Levy, Estrella Mariel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159755/
https://www.ncbi.nlm.nih.gov/pubmed/30294328
http://dx.doi.org/10.3389/fimmu.2018.02140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159755/
https://www.ncbi.nlm.nih.gov/pubmed/30294328
http://dx.doi.org/10.3389/fimmu.2018.02140

Ejemplares similares